Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995771 | 0.95 | KDM4E (0.52) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL13995859 | 0.95 | KDM4E (0.52) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL20324133 | 0.93 | KDM4E (0.56) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL11058231 | 0.93 | KDM4E (0.56) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL13995774 | 0.93 | KDM4E (0.56) | KDM4EANPEPERAP2HTTSMN1; SMN2 | |
| SCHEMBL21799566 | 0.82 | KDM1A (0.33) | KDM4EANPEPERAP2 | |
| SCHEMBL6986244 | 0.82 | — | — | |
| SCHEMBL21799480 | 0.80 | SMYD3 (0.38) | KDM4EANPEPERAP2MCHR1 | |
| SCHEMBL22084809 | 0.77 | KDM4E (0.37) | KDM4ESMN1; SMN2CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL28831952 | 0.77 | KDM4E (0.48) | KDM4EANPEPERAP2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10792292-B2 | Abiraterone prodrugs | PROPELLA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792292-B2 | Abiraterone prodrugs | CYP21A2, SHBG, CYP17A1 | KDM4E 4285/4885ANPEP 502/4885ERAP2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.